Lantheus Holdings Expands Alzheimer’s
Lantheus Holdings Expands Alzheimer’s Diagnostics Despite Recent Stock Dip
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a Massachusetts-based company specializing in radiopharmaceuticals and diagnostic imaging. Through Lantheus Medical Imaging, Progenics, and EXINI, the company develops and commercializes precision diagnostics and radiotherapeutics used in oncology and cardiology. It is supported by strategic partnerships from global healthcare leaders.
Lantheus Holdings, Inc. is one of the 11 Best Long Term Low Risk Stocks to Invest in. The company completes the acquisition of Life Molecular Imaging Limited amid a fall in the monthly and weekly performance of shares.
Lantheus Holdings, Inc. announced the completion of the acquisition of Life Molecular Imaging Limited. With the $350 million acquisition and the addition of Neuraceq, an F-18 PET imaging agent, Lantheus Holdings, Inc. increases its capabilities in Alzheimer’s disease diagnostics.
On the other hand, the company’s weekly and monthly performance were down by 10.98% and 8.65%, respectively. These declines follow the expiration of the company’s transitional pass-through payment status for its product PYLARIFY and the subsequent implementation of the mean unit cost pricing for Medicare fee-for-service coverage.
However, analysts, including Truist Financial and TD Cowen, stick to their Buy rating on the stock, signaling confidence in the company’s future growth.
Lantheus Holdings, Inc. is anticipated to incur an 8.36% EPS growth in the next 5 years, and it currently has a low beta of 0.15, which makes the stock a good buy for investors seeking long term stocks with low risks.
